Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

NCT00680225 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Choroidal Melanoma

Interventions

DRUG: Ranibizumab injection and TTT - ICG based

Sponsor

New England Retina Associates